Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T).

@article{Riddler1995AntiretroviralAO,
  title={Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T).},
  author={Sharon A. Riddler and Rachel E Anderson and John W Mellors},
  journal={Antiviral research},
  year={1995},
  volume={27 3},
  pages={189-203}
}
Stavudine, 2',3'-didehydro-3'-deoxythymidine (D4T), is a potent inhibitor of HIV-1 reverse transcriptase in vitro. In clinical studies, stavudine has excellent oral bioavailability in excess of 80%. The dose-limiting toxicity is peripheral neuropathy, which occurred in 15% of stavudine versus 6% of zidovudine-treated patients for 80 weeks in a randomized, blinded, phase III trial. Stavudine-treated groups have experienced significant increases in mean CD4 cell counts and decreases in both mean… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys.

Drug metabolism and disposition: the biological fate of chemicals • 1997
View 1 Excerpt

Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice.

Drug metabolism and disposition: the biological fate of chemicals • 1997
View 1 Excerpt

Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats.

Drug metabolism and disposition: the biological fate of chemicals • 1997
View 1 Excerpt

Similar Papers

Loading similar papers…